Evidence map›Paper›PMID 26712231›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Samira M Sadowski, Vladimir Neychev, Corina Millo, Joanna Shih, Naris Nilubol, Peter Herscovitch, Karel Pacak, Stephen J Marx, Electron Kebebew

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07064746 (Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma), which is not on this map. Cited by 184 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07064746 recruitingnot on this mapstarted 2022, after this paper: background citation

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

Typeobservational_patient_registrySponsorNanjing First Hospital, Nanjing Medical UniversityRan2022 to 2027Enrolled150ConditionsNeuroblastoma (NB)Arms¹²³I-MIBG SPECT/CT, SSTR PET
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Guideline
  4. Guideline
  5. Survival predictors ofJournal of cancer research and clinical oncology · 2022
    Trial
  6. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Synthesis, preclinical evaluation, and clinical translation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  16. Non-FDG PET/CT.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  17. Article
  18. Frontiers in endocrinology · 2026
    Article
  19. Article
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samira M SadowskiAll authors: National Institutes of Health, Bethesda, MD.
Vladimir NeychevAll authors: National Institutes of Health, Bethesda, MD.
Corina MilloAll authors: National Institutes of Health, Bethesda, MD.
Joanna ShihAll authors: National Institutes of Health, Bethesda, MD.
Naris NilubolAll authors: National Institutes of Health, Bethesda, MD.
Peter HerscovitchAll authors: National Institutes of Health, Bethesda, MD.
Karel PacakAll authors: National Institutes of Health, Bethesda, MD.
Stephen J MarxAll authors: National Institutes of Health, Bethesda, MD.
Electron KebebewAll authors: National Institutes of Health, Bethesda, MD. electron.kebebew@nih.gov.

Funding

Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and ParagangliomaZIAHD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2009 to 2024
$28.4M
Intramural NIH HHS
6 · The paper itself

Abstract

purposeGastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasing in incidence, and accurate staging is important for selecting the appropriate treatment. (68)Ga-DOTATATE imaging is a promising approach for detecting GEPNETs and could help in selecting optimal therapeutic strategies. The aim of this study was to prospectively determine the clinical utility of (68)Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) in detecting unknown primary and metastatic GEPNETs. PATIENTS AND

methodsOne hundred thirty-one patients were enrolled in a prospective study of patients undergoing (68)Ga-DOTATATE PET/CT, (111)In-pentetreotide single-photon emission computed tomography (SPECT)/CT and multiphasic CT scan, and/or magnetic resonance imaging in a blinded fashion with comprehensive biochemical testing. The primary outcome measure was the detection of lesions by each imaging study.

results(68)Ga-DOTATATE PET/CT imaging detected 95.1% of lesions (95% CI, 92.4% to 96.8%) with an average maximum standardized uptake value of 65.4 ± 47 (range, 6.9 to 244), anatomic imaging detected 45.3% of lesions (95% CI, 37.9% to 52.9%), and (111)In-pentetreotide SPECT/CT detected 30.9% of lesions (95% CI, 25.0% to 37.5%), with a significant difference between imaging modalities (P < .001). In four of 14 patients (28.6%), (68)Ga-DOTATATE PET/CT found a previously unknown primary tumor, and detected primary GEPNET, lymph node, and distant metastases correctly in 72 of 113 lesions (63.7%) when compared with histopathology, with 22.1% and 38.9% detected by using (111)In-pentetreotide SPECT/CT and anatomic imaging, respectively. On the basis of findings with (68)Ga-DOTATATE PET/CT, 43 of 131 patients (32.8%) had a change in management recommendation. In patients with carcinoid symptoms but negative biochemical testing, (68)Ga-DOTATATE PET/CT detected lesions in 65.2% of patients, 40% of which were detected neither by anatomic imaging nor by (111)In-pentetreotide SPECT/CT.

conclusion(68)Ga-DOTATATE PET/CT imaging provides important information for accurate staging of GEPNETs and selection of appropriate treatment interventions even in the absence of biochemical evidence of disease in symptomatic patients.

Indexed as

Positron-Emission TomographyTomography, X-Ray ComputedAdultAgedAged, 80 and overChromogranin AFemaleHumansHydroxyindoleacetic AcidIntestinal NeoplasmsLiver NeoplasmsLymphatic MetastasisMagnetic Resonance ImagingMaleMiddle AgedMultimodal ImagingChromogranin Agallium Ga 68 dotatateHydroxyindoleacetic AcidOrganometallic CompoundsPancreatic PolypeptidepentetreotidePhosphopyruvate HydrataseSomatostatinVasoactive Intestinal Peptide

Identifiers

PMID26712231
PMCPMC4872030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.